Coroners warns of drugs combination following nurse's death
The inquest into Ms Burgess' death, held last month, heard she had been prescribed heart medication after a diagnosis of sinus tachycardia - a faster than normal heartbeat.She had also been prescribed antidepressant medication. In a report sent to National Institute for Health and Care Excellence (Nice) and the Royal College of Physicians, Mr Walker said the potential danger of the combination of the drugs was "not well-known or appreciated" by those treating her.She had been using the combination of drugs for four years before she died without concern, the inquest heard. The coroner returned a narrative conclusion, recording that Ms Burgess died from natural causes contributed to by the effect of medication in combination.His report said: "It is likely that the medication interacted with each other to raise the levels of amitriptyline in Chloe's blood."His PFD report said this, combined with her heart medication and an episode of sleep apnoea - where breathing stops and starts during sleep - induced "sudden cardiac death".He said the inquest had heard the combination of amitriptyline, paroxetine and ivabradine does not trigger an alert on the prescribing software used in primary care or by pharmacists."In my opinion there is a risk that future deaths could occur unless action is taken," he said.
You can follow BBC Hampshire & Isle of Wight on Facebook, X (Twitter), or Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
Millions to benefit as online NHS programmes given green light
Millions of people with heart problems in the UK will soon be able to complete rehabilitation programmes online from their homes. The National Institute for Health and Care Excellence (Nice) has conditionally recommended six digital platforms for use by the NHS. These platforms aim to transform cardiac care delivery, addressing low uptake of traditional programmes and reaching underserved patient groups. The online programmes offer exercise routines, dietary advice, medication management, psychological support, and some include wearable device integration. The six platforms will be used on the NHS for three years to gather further evidence on their long-term effectiveness, with a public consultation open until September 3.
Glasgow Times
4 hours ago
- Glasgow Times
Heart patients to be offered rehab online under new draft guidance
Experts said the programmes 'offer real potential to transform' how this type of care is delivered to individual patients. Six online platforms have been conditionally recommended to support adults with cardiovascular disease (CVD) in new draft guidance from the National Institute for Health and Care Excellence (Nice). They are Activate Your Heart, D REACH-HF, Digital Heart Manual, Gro Health HeartBuddy, KiActiv and myHeart. CVD is a general term for conditions that impact the heart or blood vessels. It is estimated that it affects around seven million people in the UK. However, uptake for cardiac rehabilitation programmes, which can reduce the risk of further heart problems and hospital admissions, is low, according to Nice. Each platform is designed to offer cardiac rehabilitation online, including exercise programmes, advice on diet, medication management and psychological support. Some of the platforms also include wearable devices to monitor activity levels. Dr Anastasia Chalkidou, healthtech programme director at Nice, said: 'These digital platforms offer real potential to transform how cardiac rehabilitation is offered to people to meet their individual circumstances. 'We know that traditional programmes aren't reaching everyone who could benefit – particularly women, younger patients and people from ethnic minority backgrounds.' Before the online platforms are offered as an option, patients must be assessed by a healthcare professional. More support may be needed for older people, those with disabilities, homeless patients or those whose first language is not English, Nice suggests. The six platforms will be used on the NHS over the next three years to generate more evidence and data on their long-term effectiveness. Dr Chalkidou added: 'The early data is promising and suggests, with safeguards in place, more people should now be given the opportunity to use these new technologies. 'This three-year evidence collection period will give us the additional robust data we need to determine whether these innovations should be recommended as a permanent part of cardiac care.' A consultation on the conditional recommendation is now underway and will close on September 3. Seven other platforms – Beat Better, Datos Health, Get Ready, Luscii vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health and Sword Move – require more research before they can be funded by the NHS, Nice said.
The Independent
7 hours ago
- The Independent
Heart patients to be offered rehab online under new draft guidance
People with heart problems will be able to complete rehabilitation online in their homes rather than waiting for face-to-face appointments after a number of platforms were conditionally given the green light for NHS use. Experts said the programmes 'offer real potential to transform' how this type of care is delivered to individual patients. Six online platforms have been conditionally recommended to support adults with cardiovascular disease (CVD) in new draft guidance from the National Institute for Health and Care Excellence (Nice). They are Activate Your Heart, D REACH-HF, Digital Heart Manual, Gro Health HeartBuddy, KiActiv and myHeart. CVD is a general term for conditions that impact the heart or blood vessels. It is estimated that it affects around seven million people in the UK. However, uptake for cardiac rehabilitation programmes, which can reduce the risk of further heart problems and hospital admissions, is low, according to Nice. Each platform is designed to offer cardiac rehabilitation online, including exercise programmes, advice on diet, medication management and psychological support. Some of the platforms also include wearable devices to monitor activity levels. Dr Anastasia Chalkidou, healthtech programme director at Nice, said: 'These digital platforms offer real potential to transform how cardiac rehabilitation is offered to people to meet their individual circumstances. 'We know that traditional programmes aren't reaching everyone who could benefit – particularly women, younger patients and people from ethnic minority backgrounds.' Before the online platforms are offered as an option, patients must be assessed by a healthcare professional. More support may be needed for older people, those with disabilities, homeless patients or those whose first language is not English, Nice suggests. The six platforms will be used on the NHS over the next three years to generate more evidence and data on their long-term effectiveness. Dr Chalkidou added: 'The early data is promising and suggests, with safeguards in place, more people should now be given the opportunity to use these new technologies. 'This three-year evidence collection period will give us the additional robust data we need to determine whether these innovations should be recommended as a permanent part of cardiac care.' A consultation on the conditional recommendation is now underway and will close on September 3. Seven other platforms – Beat Better, Datos Health, Get Ready, Luscii vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health and Sword Move – require more research before they can be funded by the NHS, Nice said.
